Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare databaseLaurent Mortier, Philippe Saïag, Astrid Blom et al.|European Journal of Cancer|2024Cited by 8
Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.A. Blom Fily, Philippe Saïag, E. Maubec et al.|Journal of Clinical Oncology|2023Cited by 3